Ajay Piramal Aims At Lead Ranks In CRAMS, OTC And Critical Care Business; Reveals Details On Abbott Deal
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Giving up one flourishing unit seems to have created larger business opportunities for a few others that form part of Indian industrialist Ajay Piramal's enterprise Piramal Healthcare
You may also be interested in...
Piramal Trims Research To Build Companions Of Neuraceq
Piramal Lifesciences has cut its research focus, eliminating drugs in the early stage development. Instead, the company will build on products that can be “companion products” to its newly launched flagship brand Neuraceq, used to detect symptoms associated with Alzheimer’s disease.
With Oxygen Healthcare Buy, India's Piramal Healthcare Breathes More Life Into Its Chemistry Skills
MUMBAI - Flush with $3.72 billion from its much publicized deal struck last year with Abbott Laboratories for its India prescriptions business, Piramal Healthcare is eyeing strategic acquisitions to strengthen its remaining businesses spanning contract research and manufacturing services, OTC drugs and critical care medications
With Oxygen Healthcare Buy, India's Piramal Healthcare Breathes More Life Into Its Chemistry Skills
MUMBAI - Flush with $3.72 billion from its much publicized deal struck last year with Abbott Laboratories for its India prescriptions business, Piramal Healthcare is eyeing strategic acquisitions to strengthen its remaining businesses spanning contract research and manufacturing services, OTC drugs and critical care medications